Zsírmáj (MASLD/MASH): vizsgálatok itt: Kína
73 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in KínaLipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 120
- Run by
- Yinzhong Shen
See details and how to joinNCT07640880 - No phaseTaking peopleDiagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
- Where
- Bengbu, Guangzhou, Haikou, Hangzhou, Hefei, Hengyang, Kunming, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Weifang, Wenzhou, Wuhan, Wuhu, Xi’an, Xuzhou, Zhengzhou, Zunyi
- Életkor
- 18 év and over
- People
- 10 000
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07632677 - No phaseTaking peopleScreening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
- Where
- Beijing
- People
- 2000
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT05330923 - 2. fázisTaking peopleA Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
- Where
- Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shiyan, Tianjin, Ürümqi, Wuhan, Xi’an
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07303803 - No phaseTaking peopleA Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
- Where
- Hangzhou
- Életkor
- 65 év to 100 év
- People
- 20 000
- Run by
- The Affiliated Hospital of Hangzhou Normal University
See details and how to joinNCT07241195 - No phaseNot yet taking people in KínaIntegrated Ultrasound-Derived Fat Fraction and 2D/4D HeartAI for Cardiovascular Risk Management in Patients With MASLD
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 700
- Run by
- First Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07545343 - No phaseTaking peopleSingle-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
- Where
- Guangzhou
- People
- 240
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07265544 - 4. fázisTaking peopleThe Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
- Where
- Jiangxi
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07272343 - No phaseTaking peopleHigh-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 100
- Run by
- Shanghai East Hospital
See details and how to joinNCT07463287 - No phaseNot yet taking people in KínaAn Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 200
- Run by
- Zhujiang Hospital
See details and how to joinNCT07455149 - Korai 1. fázisNot yet taking people in KínaA Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
- Where
- Jilin City
- Életkor
- 18 év to 65 év
- People
- 94
- Run by
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
See details and how to joinNCT07407634 - Korai 1. fázisTaking peopleEfficacy and Safety of Rifaximin-α in Treating MASLD
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07381257 - 2. fázisTaking peopleA Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
- Where
- Beijing, Chengdu
- Életkor
- 18 év to 65 év
- People
- 80
- Run by
- Hinova Pharmaceuticals Inc.
See details and how to joinNCT07308548 - 2/3. fázisTaking peopleThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 20
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07285850 - Korai 1. fázisTaking peopleEfficacy and Safety of Rifaximin in Treating MAFLD
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07185932 - No phaseNot yet taking people in KínaCPET-based HIIT for MAFLD
- Where
- Beijing
- Életkor
- 35 év to 65 év
- People
- 54
- Run by
- Tang Yida
See details and how to joinNCT07177963 - No phaseTaking peopleTo Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
- Where
- Wuhan
- People
- 500
- Run by
- Tongji Hospital
See details and how to joinNCT07149571 - 1. fázisTaking peoplea Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease(NAFLD)
- Where
- Beijing, Datong, Guangzhou, Tianjin, Wenzhou
- Életkor
- 18 év to 75 év
- People
- 32
- Run by
- Tasly Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07128797 - No phaseTaking peopleLiver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
- Where
- Changsha, Yichang
- Életkor
- 18 év to 75 év
- People
- 120
- Run by
- State Key Laboratory of Subhealth Intervention Technology
See details and how to joinNCT05439226 - No phaseNot yet taking people in KínaEfficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Huazhong University of Science and Technology
See details and how to joinNCT07085962 - No phaseNot yet taking people in KínaA Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
- Where
- Beijing, Changsha, Changzhi, Foshan, Fuzhou, Guangzhou, Guiyang, Jincheng, Jinzhong, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shiyan, Taiyuan, Zhuhai
- Életkor
- 18 év to 75 év
- People
- 735
- Run by
- Beijing Friendship Hospital
See details and how to joinNCT07087041 - No phaseNot yet taking people in KínaPrognostic Model for MASLD Related Cirrhosis
- Where
- Beijing, Tianjin
- Életkor
- 18 év to 80 év
- People
- 228
- Run by
- Beijing Friendship Hospital
See details and how to joinNCT07082751 - No phaseTaking peopleLiver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
- Where
- Changsha, Yichang
- Életkor
- 18 év and over
- People
- 120
- Run by
- State Key Laboratory of Subhealth Intervention Technology
See details and how to joinNCT07083336 - 1/2. fázisNot yet taking people in KínaTo Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH
- Where
- Changchun
- Életkor
- 18 év to 65 év
- People
- 40
- Run by
- Changchun Intellicrown Pharmaceutical Co. LTD
See details and how to joinNCT07016633 - No phaseTaking peopleAccelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
- Where
- Ningbo
- Életkor
- 20 év to 90 év
- People
- 2720
- Run by
- Ningbo No. 1 Hospital
See details and how to joinNCT06984510